PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPiperaquine phosphate
Piperaquine tetraphosphate
Eurartesim (piperaquine tetraphosphate) is a small molecule pharmaceutical. Piperaquine tetraphosphate was first approved as Eurartesim on 2011-10-27. It has been approved in Europe to treat malaria.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
P01: Antiprotozoals
P01B: Antimalarials
P01BF: Artemisinin and derivatives, combinations
P01BF05: Artenimol and piperaquine
P01BF07: Artemisinin and piperaquine
P01BX: Other antimalarials in atc
P01BX02: Arterolane and piperaquine
HCPCS
No data
Clinical
Clinical Trials
69 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B5414132014660
Falciparum malariaD016778EFO_0007444B506996329
AnemiaD000740EFO_0004272D64.9134
Vivax malariaD016780EFO_0007445B5111114
PregnancyD011247EFO_0002950Z33.1123
Treatment adherence and complianceD00007482211
PharmacokineticsD01059911
Hiv infectionsD015658EFO_0000764B2011
Drug interactionsD00434711
Glucosephosphate dehydrogenase deficiencyD005955EFO_000728711
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Disease susceptibilityD00419811
FeverD005334R50.911
TherapeuticsD01381211
Filarial elephantiasisD004605EFO_0007272B74.011
ScabiesD012532B8611
StrongyloidiasisD013322EFO_0007501B7811
FilariasisD005368B7411
African trypanosomiasisD014353B5611
AncylostomatoideaD00072311
ElephantiasisD004604EFO_000471111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CardiotoxicityD066126EFO_100148211
ParasitemiaD01851211
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_000054411
Communicable diseasesD00314111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePiperaquine tetraphosphate
INN
Description
Piperaquine is an aminoquinoline that is 1,3-di(piperazin-1-yl)propane in which the nitrogen at position 4 of each of the piperazine moieties is replaced by a 7-chloroquinolin-4-yl group. It has a role as an antimalarial. It is a N-arylpiperazine, an organochlorine compound and an aminoquinoline.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O
Identifiers
PDB
CAS-ID4085-31-8
RxCUI
ChEMBL IDCHEMBL1652442
ChEBI ID
PubChem CID122262
DrugBankDB13941
UNII ID
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 431 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
35 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use